

1646


PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0654-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

to be used for all correspondence after initial filing)

TRANSMITTAL FORM to be used for all correspondence after initial filing)	Application Number	09/935,366	
	Filing Date	August 22, 2001	
	First Named Inventor	J. Fernando Bazan	
	Group Art Unit	1646	
	Examiner Name	Joseph F. Murphy, Ph.D.	
Total Number of Pages in This Submission	1	Attorney Docket Number	015631-004801US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Attachments – 2 Articles Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm and Individual name	Townsend and Townsend and Crew LLP Hugh Wang Reg. No. 47,163
Signature	
Date	March 20, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>March 20, 2002</u>	
Typed or printed name	Kathy Johnston
Signature	
Date	March 20, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3209248 v1



PATENT
Attorney Docket No.: 15631-0004801US
Client Docket No.: DX0758K1-RE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

48/murphy
4-2-02

In re Application of J. Fernando Bazan

Examiner: Joseph F. Murphy, Ph.D.

Application No.: 09/935,366

Art Unit: 1646

Filed: August 22, 2001

For: DNA ENCODING INTERLEUKIN-
B30

Response to Office Action

RECEIVED

APR 01 2002

TECH CENTER 1600/2900 -

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the non-final Office Action mailed January 2, 2002 in the above-captioned application, please consider and enter the following claim amendments and remarks.

IN THE CLAIMS

✓ Please cancel claims 8 and 11 without prejudice to subsequent renewal or future prosecution. Please amend claims 1, 3, 4, 10, 16, and 17 as follows. A marked-up version of all pending claims is shown in the attached Appendix.

- bl
1. (Twice Amended) An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising:
- a) at least 132 contiguous amino acids from a mature coding portion of SEQ ID NO: 2;
- b) at least 17 contiguous amino acids from a mature coding portion of SEQ ID NO: 4; or
- c) at least 30 contiguous amino acids from a mature coding portion of SEQ ID NO: 5.